A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Clinical trial NCT06111235 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06111235
Sponsor: CG Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non Muscle Invasive Bladder Cancer Urologic Cancer Bladder Cancer Urothelial Carcinoma

Start date: 2023-12-14
Primary completion: 2026-11-01
Enrollment: 367

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.